DXP 006
Alternative Names: DXP-006Latest Information Update: 21 Aug 2024
Price :
$50 *
At a glance
- Originator Singlomics Biopharmaceuticals
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders; Inflammation
Most Recent Events
- 29 Jul 2024 Early research in Inflammation in China (Parenteral) prior to July 2024 (Singlomics Biopharmaceuticals pipeline, July 2024)
- 29 Jul 2024 Early research in Immunological disorders in China (Parenteral) prior to July 2024 (Singlomics Biopharmaceuticals pipeline, July 2024)